Equities research analysts expect GenMark Diagnostics, Inc (NASDAQ:GNMK) to report ($0.24) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for GenMark Diagnostics’ earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.28). GenMark Diagnostics posted earnings of ($0.27) per share during the same quarter last year, which would indicate a positive year over year growth rate of 11.1%. The firm is scheduled to issue its next earnings results after the market closes on Tuesday, February 27th.
On average, analysts expect that GenMark Diagnostics will report full year earnings of ($1.18) per share for the current year, with EPS estimates ranging from ($1.23) to ($1.11). For the next financial year, analysts anticipate that the business will report earnings of ($0.85) per share, with EPS estimates ranging from ($0.99) to ($0.71). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for GenMark Diagnostics.
A number of analysts recently commented on the stock. BTIG Research set a $11.00 target price on shares of GenMark Diagnostics and gave the stock a “buy” rating in a research note on Tuesday, January 16th. BidaskClub cut shares of GenMark Diagnostics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 2nd. Zacks Investment Research upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. Raymond James Financial reiterated a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of GenMark Diagnostics in a research note on Friday, January 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $11.80.
GenMark Diagnostics (NASDAQ:GNMK) traded down $0.21 during trading hours on Tuesday, hitting $4.25. 333,100 shares of the stock were exchanged, compared to its average volume of 469,517. The company has a market cap of $244.39, a PE ratio of -3.41 and a beta of 0.78. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12. GenMark Diagnostics has a twelve month low of $3.63 and a twelve month high of $13.67.
In other GenMark Diagnostics news, insider Hany Massarany sold 6,584 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $4.37, for a total transaction of $28,772.08. Following the completion of the transaction, the insider now directly owns 357,190 shares of the company’s stock, valued at approximately $1,560,920.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 21,836 shares of company stock valued at $100,151 over the last three months. 7.50% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Wrapmanager Inc. raised its position in GenMark Diagnostics by 121.3% during the 4th quarter. Wrapmanager Inc. now owns 39,547 shares of the medical equipment provider’s stock worth $165,000 after buying an additional 21,679 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in GenMark Diagnostics by 111.1% during the 4th quarter. UBS Asset Management Americas Inc. now owns 49,400 shares of the medical equipment provider’s stock worth $206,000 after buying an additional 26,000 shares during the last quarter. OLD National Bancorp IN raised its position in GenMark Diagnostics by 120.6% during the 4th quarter. OLD National Bancorp IN now owns 49,765 shares of the medical equipment provider’s stock worth $208,000 after buying an additional 27,208 shares during the last quarter. Fairpointe Capital LLC purchased a new position in GenMark Diagnostics during the 4th quarter worth approximately $220,000. Finally, FDx Advisors Inc. raised its position in GenMark Diagnostics by 124.1% during the 4th quarter. FDx Advisors Inc. now owns 53,689 shares of the medical equipment provider’s stock worth $224,000 after buying an additional 29,729 shares during the last quarter.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect GenMark Diagnostics, Inc (GNMK) Will Post Earnings of -$0.24 Per Share” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/23/zacks-analysts-expect-genmark-diagnostics-inc-gnmk-will-post-earnings-of-0-24-per-share.html.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Get a free copy of the Zacks research report on GenMark Diagnostics (GNMK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.